Somewhat Positive News Coverage Somewhat Unlikely to Affect Repligen Corporation (RGEN) Stock Price

News coverage about Repligen Corporation (NASDAQ:RGEN) has been trending somewhat positive on Wednesday, according to Accern. The research firm identifies positive and negative media coverage by reviewing more than twenty million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. Repligen Corporation earned a daily sentiment score of 0.08 on Accern’s scale. Accern also assigned headlines about the biotechnology company an impact score of 47.2854741220157 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the next several days.

Here are some of the headlines that may have effected Accern Sentiment’s rankings:

Repligen Corporation (NASDAQ:RGEN) traded down $0.59 during mid-day trading on Wednesday, reaching $33.91. 134,876 shares of the company traded hands, compared to its average volume of 326,247. The firm has a market capitalization of $1,500.00, a price-to-earnings ratio of 57.35, a PEG ratio of 2.20 and a beta of 1.05. Repligen Corporation has a 52 week low of $28.48 and a 52 week high of $46.81.

Repligen Corporation (NASDAQ:RGEN) last posted its quarterly earnings data on Thursday, November 9th. The biotechnology company reported $0.15 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $0.11 by $0.04. The business had revenue of $36.58 million for the quarter, compared to the consensus estimate of $35.69 million. Repligen Corporation had a net margin of 16.93% and a return on equity of 7.57%. The company’s revenue was up 48.2% compared to the same quarter last year. During the same period last year, the firm posted $0.08 earnings per share. analysts predict that Repligen Corporation will post 0.61 EPS for the current fiscal year.

A number of research analysts have issued reports on the stock. Stephens restated an “overweight” rating and set a $50.00 price target on shares of Repligen Corporation in a research note on Tuesday, September 26th. Jefferies Group LLC reiterated a “hold” rating and issued a $40.00 price objective on shares of Repligen Corporation in a research note on Thursday, September 14th. BidaskClub upgraded shares of Repligen Corporation from a “hold” rating to a “buy” rating in a research note on Wednesday, August 9th. TheStreet upgraded shares of Repligen Corporation from a “c+” rating to a “b-” rating in a research note on Friday, August 11th. Finally, Zacks Investment Research upgraded shares of Repligen Corporation from a “hold” rating to a “buy” rating and set a $46.00 price objective on the stock in a research note on Saturday, August 12th. Two equities research analysts have rated the stock with a hold rating and five have issued a buy rating to the stock. The company presently has a consensus rating of “Buy” and an average target price of $44.67.

COPYRIGHT VIOLATION NOTICE: This report was originally reported by Transcript Daily and is the property of of Transcript Daily. If you are viewing this report on another publication, it was illegally stolen and republished in violation of international copyright & trademark law. The correct version of this report can be viewed at

Repligen Corporation Company Profile

Repligen Corporation is a bioprocessing company. The Company is focused on the development, manufacture and commercialization of products used to improve the interconnected phases of the biological drug manufacturing process. The Company’s portfolio includes protein products, chromatography products, and filtration products.

Insider Buying and Selling by Quarter for Repligen Corporation (NASDAQ:RGEN)

Receive News & Ratings for Repligen Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Repligen Corporation and related companies with's FREE daily email newsletter.

Leave a Reply